Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Lear boosts share buyback authorization to $1.5 billion through 2029
• Costco (COST) Tops Q4 EPS by 20c